Contrasting Surrozen (NASDAQ:SRZN) & AbCellera Biologics (NASDAQ:ABCL)

Surrozen (NASDAQ:SRZN) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Volatility and Risk

Surrozen has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.

Insider and Institutional Ownership

66.6% of Surrozen shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 31.7% of Surrozen shares are held by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Surrozen and AbCellera Biologics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48 million	96.88	-$242.03 million	($40.55)	-0.72
AbCellera Biologics	$75.13 million	50.07	-$146.41 million	($0.54)	-22.72

AbCellera Biologics has higher revenue and earnings than Surrozen. AbCellera Biologics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Surrozen and AbCellera Biologics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1	1	4	1	2.71
AbCellera Biologics	1	2	6	2	2.82

Surrozen currently has a consensus target price of $48.33, suggesting a potential upside of 66.44%. AbCellera Biologics has a consensus target price of $14.60, suggesting a potential upside of 18.99%. Given Surrozen’s higher possible upside, research analysts plainly believe Surrozen is more favorable than AbCellera Biologics.

Profitability

This table compares Surrozen and AbCellera Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Surrozen	-2,885.33%	N/A	-93.62%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

Summary

AbCellera Biologics beats Surrozen on 9 of the 15 factors compared between the two stocks.

About Surrozen

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

About AbCellera Biologics

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.